Skip to main content
SpringerLink
Log in

Biologic response-modifying agents: What is an appropriate phase I–II strategy?

  • Editorial
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carter SK (1977) Clinical trials in cancer chemotherapy. Cancer 40:554–557

    Google Scholar 

  2. Goldsmith MA, Slavik M, Carter SK (1975) Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35:1354–1364

    Google Scholar 

  3. O'Connell MJ, Moertel CJ, Ritts RE, Jr, Frytak S, Reitemeir RJ (1979) A comparative clinical and immunological assessment of methanol extraction residue of Bacillus Calmette-Guérin vs. placebo in patients with advanced cancer. Cancer Res 39:3720–3724

    Google Scholar 

  4. Skipper HE, Schabel FM, Wilcox WS (1964) Experimental evaluation of potential anticancer agents XIII. On the criteria and kinetics associated with “curability” of experimental tumors. Cancer Chemother Rep 35:1–111

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1801 Page Mill Road, Building B, Suite 200, 94304, Palo Alto, CA, USA

    S. K. Carter (Director Northern California Cancer Program)

  2. Stanford University, San Francisco

    S. K. Carter (Director Northern California Cancer Program)

  3. University of California, San Francisco

    S. K. Carter (Director Northern California Cancer Program)

Authors
  1. S. K. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carter, S.K. Biologic response-modifying agents: What is an appropriate phase I–II strategy?. Cancer Immunol Immunother 8, 207–210 (1980). https://doi.org/10.1007/BF00206036

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00206036

Search

Navigation